While a preclinical analysis revealed that no significant OS improvement after PMRT was found in HER2‐enriched high‐risk breast cancer patients,24 HER2 + was shown as a predictor for favorable survival compared with the HER2‐ in RT‐treated patients in our study. Here, ERBB2 is linked to breast carcinoma.